MX2020006658A - Treatment of exercise-induced hypoglycemia in type 1 and insulin using type 2 diabetes. - Google Patents

Treatment of exercise-induced hypoglycemia in type 1 and insulin using type 2 diabetes.

Info

Publication number
MX2020006658A
MX2020006658A MX2020006658A MX2020006658A MX2020006658A MX 2020006658 A MX2020006658 A MX 2020006658A MX 2020006658 A MX2020006658 A MX 2020006658A MX 2020006658 A MX2020006658 A MX 2020006658A MX 2020006658 A MX2020006658 A MX 2020006658A
Authority
MX
Mexico
Prior art keywords
type
exercise
insulin
diabetes
treatment
Prior art date
Application number
MX2020006658A
Other languages
Spanish (es)
Inventor
Steven Prestrelski
Brett Newswanger
Martin Cummins
Michael Riddell
Original Assignee
Xeris Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xeris Pharmaceuticals Inc filed Critical Xeris Pharmaceuticals Inc
Publication of MX2020006658A publication Critical patent/MX2020006658A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

Certain embodiments are directed to methods for treating, ameliorating, or preventing exercise-induced or exercise-associated hypoglycemia comprising administration to a subject in need thereof a formulation(s) of glucagon or glucagon analog in an amount effective to treat, ameliorate, or prevent the condition. The subject can be administered a glucagon or a glucagon analog composition 1, 5, 10, 15 to 20, 25, 30 minutes prior to initiation of exercise.
MX2020006658A 2017-12-22 2018-12-21 Treatment of exercise-induced hypoglycemia in type 1 and insulin using type 2 diabetes. MX2020006658A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762609964P 2017-12-22 2017-12-22
PCT/US2018/067294 WO2019126753A1 (en) 2017-12-22 2018-12-21 Treatment of exercise-induced hypoglycemia in type 1 and insulin using type 2 diabetes

Publications (1)

Publication Number Publication Date
MX2020006658A true MX2020006658A (en) 2020-11-06

Family

ID=65139204

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020006658A MX2020006658A (en) 2017-12-22 2018-12-21 Treatment of exercise-induced hypoglycemia in type 1 and insulin using type 2 diabetes.

Country Status (9)

Country Link
US (2) US20210008170A1 (en)
EP (1) EP3727427A1 (en)
JP (1) JP2021506933A (en)
KR (1) KR20200103029A (en)
CN (1) CN111565740A (en)
AU (1) AU2018388417A1 (en)
BR (1) BR112020012268A2 (en)
MX (1) MX2020006658A (en)
WO (1) WO2019126753A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020284104A1 (en) 2019-05-31 2021-12-16 Xeris Pharmaceuticals, Inc. Stable therapeutic compositions in aprotic polar solvents and methods of manufacturing the same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012122535A2 (en) * 2011-03-10 2012-09-13 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of peptide drugs
WO2013086292A1 (en) * 2011-12-09 2013-06-13 Enject, Inc. Glucagon formulations
US9018162B2 (en) * 2013-02-06 2015-04-28 Xeris Pharmaceuticals, Inc. Methods for rapidly treating severe hypoglycemia
DK3102184T3 (en) * 2014-02-06 2019-05-06 Xeris Pharmaceuticals Inc STABLE FORMULATIONS OF PEPTIDES AND PROCEDURES FOR PREPARATION
WO2016069409A1 (en) * 2014-10-27 2016-05-06 Latitude Pharmaceuticals, Inc. Parenteral glucagon formulations
US9649364B2 (en) * 2015-09-25 2017-05-16 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic formulations in aprotic polar solvents
WO2016196976A1 (en) * 2015-06-04 2016-12-08 Xeris Pharmaceuticals, Inc. Glucagon delivery apparatuses and related methods
WO2016201248A1 (en) * 2015-06-10 2016-12-15 Xeris Pharmaceuticals, Inc. Use of low dose glucagon

Also Published As

Publication number Publication date
EP3727427A1 (en) 2020-10-28
US20210008170A1 (en) 2021-01-14
BR112020012268A2 (en) 2020-11-24
US20240016898A1 (en) 2024-01-18
WO2019126753A1 (en) 2019-06-27
JP2021506933A (en) 2021-02-22
CN111565740A (en) 2020-08-21
AU2018388417A1 (en) 2020-07-02
KR20200103029A (en) 2020-09-01

Similar Documents

Publication Publication Date Title
TN2017000426A1 (en) Pharmaceutical compositions for combination therapy
ZA202103366B (en) Composition for treating diabetes based on chinese medical nutrition therapy and application of composition
PH12018501424B1 (en) A composition for treating diabetes or diabesity comprising oxyntomodulin analog
MY191321A (en) Glucagon and glp-1 co-agonists for the treatment of obesity
PH12017501222A1 (en) Glucagon derivatives with improved stability
MX2018001435A (en) Methods of treating lennox-gastaut syndrome using fenfluramine.
MX2019013279A (en) Methods of treating doose syndrome using fenfluramine.
AR049955A1 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS
JOP20200156A1 (en) Esketamine for the treatment of depression
MX2019003173A (en) Combination therapy with controlled-release cnp agonists.
MX2017005134A (en) Treatment of cancer with immune stimulators.
MX2020006284A (en) Bis-choline tetrathiomolybdate for treating wilson disease.
MX2020001342A (en) Use of gaboxadol in the treatment of diabetes and related conditions.
MX2023000187A (en) Dosing of vibegron for treatment of overactive bladder.
RU2013132566A (en) THERAPEUTIC AGAINST HERNIASIS
TN2017000040A1 (en) Medical treatments based on anamorelin
MX2020006658A (en) Treatment of exercise-induced hypoglycemia in type 1 and insulin using type 2 diabetes.
CR20210514A (en) Use of reboxetine to treat narcolepsy
MX2020001768A (en) Methods of treatment of osteoarthritis with transdermal cannabidiol gel.
EP3758689A4 (en) Methods of preventing and treating hypoglycemia in type 1 and type 2 diabetes patients
MX2021001228A (en) Composition for use in the prevention and/or treatment of the genitourinary mucosa.
EA201592058A1 (en) APPLICATION OF LANDIOLOL HYDROCHLORIDE IN LONG-TERM TREATMENT OF TACHIHARITHMIA
MX2023001388A (en) Therapeutic agent for nerve disfunction.
Park Hypopigmentation, muscle-atrophy, nerve injury, and subcutaneous fat atrophy: case report
MX2022002947A (en) Avocatin b for the treatment of diseases and conditions.